Suppliers / Serum Institute Of India

Serum Institute Of India

India 2 duplicate records merged Updated 9 July 2026

Serum Institute Of India is a finished-dose manufacturer based in India. It appears in 267 regulatory filings across 20 regulators, without an active US DMF or CEP on file. Its filings concentrate with CDSCO (India), NPRA (MY) and NMRC (NA). Its GMP standing is certified by EMA, ANVISA (Brazil) and MHRA (UK), among 7 authorities. Its most recent recorded inspection, by US FDA, closed on 2 July 2024 as VAI. Customs aggregates show $1.0B of exports covering 4,051 molecules to 165 destinations in 2025.

0
active US DMFs
0
valid CEPs
7
registered plants 1 with an FDA FEI number
267
filings across 20 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 2 July 2024 VAI US FDA
  • 19 April 2022 VAI US FDA
  • 13 December 2011 VAI US FDA
  • 28 January 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Pune, United Arab Emirates Not on file
Pune, United Arab Emirates Not on file
Pune, United Arab Emirates Not on file
India, Colombia Not on file
Pune, India 3020223359
PUNE, India Not on file

1 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 64 None
NPRA (MY) 23 None
NMRC (NA) 19 None
TMDA (TZ) 18 None
UZPHARM (UZ) 17 None
EFDA (ET) 15 None
EMA None 6
ANVISA (Brazil) None 3
MHRA (UK) None 2
FDA (GH) None 2
NAFDAC (NG) None 1
INVIMA (CO) None 1
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $183.6M 121
2025 Not reported $1.0B 165
2024 Not reported $744.0M 162
2023 Not reported $830.0M 160

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Serum Institute Of India comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 2 July 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts